Report type:
Research program:
Year published:
2021
Monitoring hepatitis C treatment uptake in Australia Issue 11, July 2021
(392.9 KB)
(392.9 KB)Description:
This report summarises data on the prescription and distribution of hepatitis C treatments and provides insight into the initial phase of the roll-out of DAA therapy in Australia.
Key findings:
- A total of 93,130 individuals have initiated direct acting antiviral (DAA) treatment for chronic hepatitis C virus (HCV) infection in Australia, including 88,790 individuals through Pharmaceutical Benefits Scheme (PBS) during 2016 to 2020, and an estimated 4,340 individuals through early DAA access avenues in 2014-15.
- It is estimated 49% of the people living with chronic HCV infection in Australia in 2015 have initiated DAA treatment (27-56% across jurisdictions).
- Among individuals initiating DAA treatment during 2016 to 2018 (n=88,790), 68% were men, and median age was 48 years (quartiles 1-3: 39-57).
Report contact:
